Natixis’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.1M | Buy |
18,018
+8,840
| +96% | +$5.67M | 0.04% | 301 |
|
|
2025
Q4 | $6.21M | Buy |
9,178
+2,779
| +43% | +$1.89M | 0.02% | 417 |
|
|
2025
Q3 | $4.09M | Buy |
6,399
+1,332
| +26% | +$808K | 0.02% | 462 |
|
|
2025
Q2 | $2.72M | Sell |
5,067
-1,998
| -28% | -$955K | 0.01% | 438 |
|
|
2025
Q1 | $2.93M | Buy |
7,065
+2,181
| +45% | +$947K | 0.02% | 376 |
|
|
2024
Q4 | $2.02M | Sell |
4,884
-353
| -7% | -$155K | 0.01% | 467 |
|
|
2024
Q3 | $2.65M | Sell |
5,237
-2,969
| -36% | -$1.44M | 0.01% | 396 |
|
|
2024
Q2 | $4M | Sell |
8,206
-16,093
| -66% | -$8.08M | 0.02% | 321 |
|
|
2024
Q1 | $13.1M | Buy |
24,299
+18,449
| +315% | +$10.1M | 0.07% | 195 |
|
|
2023
Q4 | $3.25M | Buy |
5,850
+1,901
| +48% | +$892K | 0.02% | 345 |
|
|
2023
Q3 | $1.73M | Sell |
3,949
-250
| -6% | -$125K | 0.01% | 419 |
|
|
2023
Q2 | $2.11M | Buy |
4,199
+3,269
| +352% | +$1.57M | 0.02% | 419 |
|
|
2023
Q1 | $465K | Sell |
930
-6,441
| -87% | -$3.08M | ﹤0.01% | 633 |
|
|
2022
Q4 | $3.01M | Buy |
7,371
+340
| +5% | +$132K | 0.02% | 468 |
|
|
2022
Q3 | $2.29M | Sell |
7,031
-328
| -4% | -$120K | 0.01% | 577 |
|
|
2022
Q2 | $2.58M | Sell |
7,359
-12,746
| -63% | -$5.2M | 0.01% | 607 |
|
|
2022
Q1 | $11M | Buy |
20,105
+2,851
| +17% | +$1.5M | 0.04% | 399 |
|
|
2021
Q4 | $11.4M | Buy |
17,254
+14,708
| +578% | +$9.23M | 0.04% | 357 |
|
|
2021
Q3 | $1.58M | Sell |
2,546
-147,685
| -98% | -$99.2M | 0.01% | 779 |
|
|
2021
Q2 | $94.9M | Buy |
150,231
+50
| +0% | +$27.6K | 0.41% | 53 |
|
|
2021
Q1 | $73.5M | Sell |
150,181
-2,347
| -2% | -$1.18M | 0.24% | 88 |
|
|
2020
Q4 | $76.2M | Sell |
152,528
-19,369
| -11% | -$8.67M | 0.28% | 80 |
|
|
2020
Q3 | $67.6M | Buy |
171,897
+126,880
| +282% | +$46.9M | 0.5% | 51 |
|
|
2020
Q2 | $14.9M | Buy |
45,017
+43,463
| +2,797% | +$12.6M | 0.12% | 146 |
|
|
2020
Q1 | $376K | Buy |
+1,554
| New | +$406K | ﹤0.01% | 611 |
|
|
2019
Q1 | – | Sell |
-13,842
| Closed | -$2.58M | – | 829 |
|
|
2018
Q4 | $2.58M | Sell |
13,842
-5,883
| -30% | -$1.21M | 0.02% | 401 |
|
|
2018
Q3 | $4.92M | Buy |
+19,725
| New | +$4.79M | 0.03% | 380 |
|
|
2018
Q2 | – | Sell |
-14,144
| Closed | -$2.71M | – | 929 |
|
|
2018
Q1 | $2.71M | Sell |
14,144
-83,577
| -86% | -$15.4M | 0.02% | 465 |
|
|
2017
Q4 | $15.3M | Sell |
97,721
-18,111
| -16% | -$2.85M | 0.12% | 170 |
|
|
2017
Q3 | $18M | Sell |
115,832
-30,452
| -21% | -$4.81M | 0.17% | 135 |
|
|
2017
Q2 | $23.6M | Buy |
146,284
+6,321
| +5% | +$1.03M | 0.27% | 97 |
|
|
2017
Q1 | $21.6M | Buy |
139,963
+135,679
| +3,167% | +$18.7M | 0.27% | 102 |
|
|
2016
Q4 | $502K | Buy |
+4,284
| New | +$489K | 0.01% | 527 |
|
Other funds holding IDXX
VCM
VPM
Natixis's IDXX Position: Q1 2026 in Review
Natixis increased its Idexx Laboratories (IDXX) stake by 96% in Q1 2026, buying an estimated $5.67M and bringing the position to 18,018 shares worth $10.1M. The position accounts for 0.04% of the portfolio, ranked #301.
Natixis first reported a position in IDXX in Q4 2016 and has held it in 33 quarters since. The position peaked at $94.9M in Q2 2021. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Natixis held 18,018 shares of Idexx Laboratories worth $10.1M as of Q1 2026.
- Natixis bought 8,840 Idexx Laboratories shares in Q1 2026, an estimated $5.67M.
- Idexx Laboratories made up 0.04% of Natixis's portfolio in Q1 2026, its #301 holding.
- Natixis first reported a position in Idexx Laboratories in Q4 2016 and has held it in 33 quarters since.
- Natixis's Idexx Laboratories position peaked at $94.9M in Q2 2021.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.